BRAF and colorectal cancer: Here, we assessed the efficacy of EGFR mAbs in simultaneous and sequential combinations with oxaliplatin in a panel of colorectal cancer cell lines with different genetic backgrounds (wild-type or mutant for KRAS or BRAF).